[go: up one dir, main page]

WO2025111453A1 - Atténuation de sps - Google Patents

Atténuation de sps Download PDF

Info

Publication number
WO2025111453A1
WO2025111453A1 PCT/US2024/056879 US2024056879W WO2025111453A1 WO 2025111453 A1 WO2025111453 A1 WO 2025111453A1 US 2024056879 W US2024056879 W US 2024056879W WO 2025111453 A1 WO2025111453 A1 WO 2025111453A1
Authority
WO
WIPO (PCT)
Prior art keywords
clinical sample
sps
polyanionic polymer
microbial
pps
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/US2024/056879
Other languages
English (en)
Inventor
Ian Wayne ANDREWS
Amanda Nicole BILLINGS-SIUTI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Day Zero Diagnostics Inc
Original Assignee
Day Zero Diagnostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Day Zero Diagnostics Inc filed Critical Day Zero Diagnostics Inc
Publication of WO2025111453A1 publication Critical patent/WO2025111453A1/fr
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1003—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6848—Nucleic acid amplification reactions characterised by the means for preventing contamination or increasing the specificity or sensitivity of an amplification reaction
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria

Definitions

  • Clinical sample processing requires selective removal of subject (e.g., human) cells from microbial cells from one or more microbial species. Microbial cells are preserved intact by the presence of one or more polyanionic polymers in a clinical sample.
  • polyanionic polymers can be useful to preserve microbial cells, they can also inhibit downstream clinical sample processing, including interfering with nucleic acid amplification.
  • the disclosure relates to the unexpected discovery that polyanionic polymers can effectively be removed from whole blood clinical samples by adding a greater amount of polyanionic polymers (e.g., sodium polyanethol sulfonate (SPS)) to the samples.
  • SPS sodium polyanethol sulfonate
  • This method also permits intact microbe preservation and subsequent molecular diagnostics of the clinical sample.
  • human patient-derived clinical samples can be rapidly processed with SPS to identify microbes that are present.
  • the present disclosure provides methods for removing a polyanionic polymer from a clinical sample.
  • the method comprises: (i) obtaining a clinical sample from a subject comprising microbial species in a container comprising between 0.01% and 1.00% of a first polyanionic polymer, (ii) adding between 0.1% and 10% of a second polyanionic polymer to the clinical sample, (iii) removing from the clinical sample from step (ii) a first fraction comprising the first polyanionic polymer and the second polyanionic polymer.
  • the present disclosure provides methods for amplifying microbial DNA in a clinical sample collected from blood.
  • the method comprises: (i) obtaining a clinical sample from a subject comprising microbial species in a container comprising between 0.01% and 1.00% of a first polyanionic polymer, (ii) adding between 0.1% and 10% of a second polyanionic polymer to the clinical sample, (iii) removing from the clinical sample from step (ii) a first fraction comprising the one or more microbial species and cells from the subject and a second fraction comprising the first polyanionic polymer and the second polyanionic polymer, (iv) lysing the one or more microbial species and cells from the subject from the first fraction, and (vi) amplifying microbial DNA from the lysed microbial species.
  • the present disclosure provides methods for amplifying microbial DNA in a clinical sample collected from blood.
  • the method comprises: (i) obtaining a clinical sample from a subject comprising microbial species in a container comprising between 0.01% and 1.00% of a first polyanionic polymer, (ii) adding between 0.1% and 10% of a second polyanionic polymer to the clinical sample, (iii) removing from the clinical sample from step (ii) a first fraction comprising the one or more microbial species and cells from the subject and a second fraction comprising the first polyanionic polymer and the second polyanionic polymer, (iv) lysing the one or more microbial species and cells from the subject from the first fraction, (v) amplifying microbial DNA from the lysed microbial species, and (vi) identifying microbial species from the amplified microbial DNA.
  • the present disclosure provides methods for removing a first polyanionic polymer (e.g., sodium polyanethol sulfonate (SPS)) in a clinical sample containing nucleic acids.
  • the method comprises: (a) adding a second polyanionic polymer to the clinical sample, (b) solubilizing polyanionic polymer-protein precipitates, and (c) removing the soluble fraction comprising the first polyanionic polymer and the second polyanionic polymer.
  • the first polyanionic polymer and the second polyanionic polymer are the same.
  • the first polyanionic polymer and the second polyanionic polymer are different.
  • the present disclosure provides methods for reducing the amount of a first polyanionic polymer (e.g., sodium polyanethol sulfonate (SPS)) in a clinical sample containing nucleic acids.
  • a first polyanionic polymer e.g., sodium polyanethol sulfonate (SPS)
  • the method comprises: (a) adding a second polyanionic polymer to the clinical sample, (b) solubilizing polyanionic polymer- protein precipitates, and (c) removing the soluble fraction comprising the first polyanionic polymer and the second polyanionic polymer.
  • the amplification is whole genome amplification.
  • adding a polyanionic polymer nucleic acid amplification inhibitor increases the amount of amplified microbial DNA between 2-fold and 100-fold, compared to control.
  • the separating is by centrifugation.
  • a first polyanionic polymer is sodium polyanethol sulfonate (SPS).
  • a second polyanionic polymer is SPS.
  • a first polyanionic polymer and a second polyanionic polymer is SPS.
  • between 0.1% and 10% of a second polyanionic polymer is added to a clinical sample comprising blood.
  • the subject is a human.
  • the microbe is a pathogenic microbe.
  • FIGS. 1A-1B illustrate that SPS forms large macromolecular aggregates with lysozyme. SPS-lysozyme aggregates form a pellet in the bottom of a tube following centrifugation (Fig. 1A). Addition of high concentration SPS prevents formation of SPS- lysozyme aggregates in a pellet following centrifugation (Fig. IB).
  • FIGs 2A-2C illustrate that high concentration SPS improves microbial DNA amplification and sequencing outputs from whole blood.
  • Addition of 0.5%, 1% or 5% SPS to whole blood samples collected in SPS vacutainers increased microbial DNA amplification by 100-fold (Fig. 2A), and increased post-quality control (QC) total number of megabases (MBs) (Fig. 2B) relative to control whole blood samples with 0% SPS added.
  • Fig. 2A Addition of 0.5%, 1% or 5% SPS to whole blood samples collected in SPS vacutainers increased microbial DNA amplification by 100-fold
  • QC post-quality control
  • MBs megabases
  • Figure 3 demonstrates that SPS mitigation process significantly increases microbial DNA recovery when using SPS containing vacutainers, compared to other anticoagulant-containing tubes, such as ACD-A, EDTA or heparin.
  • the dotted line illustrates the normalized bacterial genome ID value.
  • Clinical sample processing for microbial identification involves collecting a clinical sample from a subject, processing the clinical sample, and identifying the microbe(s) present in the clinical sample.
  • This clinical sample processing relies on preserving intact microbial cells to enable their processing and identification.
  • One or more polyanionic polymers may be added to clinical samples to preserve intact microbial (e.g., bacterial) cells by inhibiting protein degradation (e.g., by the complement pathway).
  • PPs may inhibit downstream molecular diagnostic reactions (e.g., amplification, sequencing) and need to either be removed from or mitigated in clinical samples in order to perform molecular diagnostic reactions utilizing the clinical samples.
  • the present disclosure is based on the unexpected finding that high concentrations of one or more PPs (e.g., SPS) added to a clinical sample (e.g., whole blood sample) already comprising PPs is effective in mitigating the PPs. Without wishing to be bound by theory, this appears to be due to the added PPs disrupting macromolecular precipitates. Disrupting macromolecular precipitates increases the efficiency of downstream molecular diagnostic reactions.
  • the present disclosure therefore provides a method for mitigating PPs in a clinical sample to enable intact microbe preservation and subsequent molecular diagnostics of the clinical sample. This method enables rapid processing of a clinical sample with PPs to identify the microbes present.
  • the present disclosure therefore advances the field of clinical sample processing and molecular diagnostics by providing methods for maintaining intact microbial cells that can be processed from collection through molecular diagnostic reactions without inhibition by PPs.
  • Other methods currently in the field rely on (1) anticoagulants such as EDTA, which does not prevent all complement pathway activity and microbial cell lysis: and/or (2) organic extractions of PPs that cause microbial cell lysis.
  • a polyanionic polymer is a non-proteinaceous substance with a molecular structure consisting of multiple similar chemical units bonded together and comprising multiple negatively-charged groups, and that has an average molecular weight of at least 500 daltons (500 Da).
  • Non-limiting examples of polyanionic polymers include: SPS, heparin, hyaluronate, dermatan sulfate polyanion, and chondroitin D-glucuronate anion.
  • a polyanionic polymer is SPS.
  • PPs may inhibit nucleic acid (e.g., DNA, RNA) amplification in a clinical sample.
  • nucleic acid e.g., DNA, RNA
  • PPs in a clinical sample may form macromolecular aggregates containing, e.g., PPs, proteins, nucleic acids (e.g., microbial, human). These macromolecular aggregates may inhibit certain molecular processes due to physical sequestration of proteins and/or nucleic acids, chelation of ions, or any other mechanism for inhibiting molecular processes.
  • macromolecular aggregates containing PPs inhibit nucleic acid amplification.
  • nucleic acid amplification may be by any method provided herein or known to a person skilled in the art.
  • PPs may be completely or partially removed from a clinical sample. In some embodiments, 10% - 100% of PPs are removed from a clinical sample. In some embodiments, 15% - 95%, 20% - 90%, 25% - 85%, 30% - 80%, 35% - 75%, 40% - 70%, 45% - 65%, or 50% - 60% of PPs are removed from a clinical sample.
  • 10%, 12%, 14%, 16%, 18%, 20%, 22%, 24%, 26%, 28%, 30%, 32%, 34%, 36%, 38%, 40%, 42%, 44%, 46%, 48%, 50%, 52%, 54%, 56%, 58%, 60%, 62%, 64%, 66%, 68%, 70%, 72%, 74%, 76%, 78%, 80%, 82%, 84%, 86%, 88%, 90%, 92%, 94%, 96%, 98%, or 100% of PPs are removed from a clinical sample by a method provided herein.
  • PPs in a clinical sample may inhibit nucleic acid amplification in a clinical sample by 10% - 100%, 15% - 95%, 20% - 90%, 25% - 85%, 30% - 80%, 35% - 75%, 40%, - 70%, 45% - 65%, or 50 - 55% compared to a control.
  • PPs may inhibit nucleic acid amplification in a clinical sample by 10%, 12%, 14%, 16%, 18%, 20%, 22%, 24%, 26%, 28%, 30%, 32%, 34%, 36%, 38%, 40%, 42%, 44%, 46%, 48%, 50%, 52%, 54%, 56%, 58%, 60%, 62%, 64%, 66%, 68%, 70%, 72%, 74%, 76%, 78%, 80%, 82%, 84%, 86%, 88%, 90%, 92%, 94%, 96%, 98%, 100% or more compared to a reference sample, such as a clinical sample that never contained a PP, or a clinical sample that has had PPs removed.
  • a reference sample such as a clinical sample that never contained a PP, or a clinical sample that has had PPs removed.
  • Clinical sample containers may include polyanionic polymers (PPs) to protect intact microbial cells during clinical sample processing.
  • PPs polyanionic polymers
  • commonly used sample collection containers, sample culture bottles, plasma tubes, and blood culture media may include heparin (e.g., Cat. Nos. 364960, 366667, 367871, 367878, 367884, 367886, 367960, 367961, 367962, and 367964 Vacutainer® collection tubes, BD Biosciences, Franklin Lakes, NJ), sodium polyanethol sulfonate (SPS, e.g., Cat. No. 364960 Vacutainer® collection tubes, Cat. Nos.
  • SPS sodium polyanethol sulfonate
  • BACTECTM PLUS media BD Biosciences, Franklin Lakes, NJ
  • potassium EDTA e.g., Cat. Nos. 367842, 367899 and 368589, Vacutainer® Plus Plastic K2EDTA Tubes, BD Biosciences, Franklin Lakes, NJ.
  • a PP is SPS.
  • SPS is an anticoagulant that prevents microbial (e.g., bacterial) lysis by innate cellular and humoral factors.
  • SPS inhibits the mammalian (e.g., human) complement system to inhibit microbial (e.g., bacterial) phagocytosis.
  • Commercial concentrations of SPS range from 0.25 mg/mL to 0.5 mg/mL.
  • a clinical sample container comprises 0.05 mg/mL - 5.0 mg/mL of a first PP.
  • a clinical sample container comprises 0.10 mg/mL - 4.9 mg/mL, 0.20 mg/mL - 4.8 mg/mL, 0.30 mg/mL - 4.7 mg/mL, 0.40 mg/mL - 4.6 mg/mL, 0.50 mg/mL - 4.5 mg/mL, 0.6 mg/mL - 4.4 mg/mL, 0.7 mg/mL - 4.3 mg/mL, 0.8 mg/mL - 4.2 mg/mL, 0.9 mg/mL - 4.1 mg/mL, 1.0 mg/mL, 4.0 mg/mL, 1.1 mg/mL - 3.9 mg/mL, 1.2 mg/mL - 3.8 mg/mL, 1.3 mg/mL - 3.7 mg/mL, 1.4 mg/mL - 3.6 mg/mL
  • a clinical sample container comprises 0.1 mg/mL, 0.2 mg/mL, 0.3 mg/mL, 0.4 mg/mL, 0.5 mg/mL, 0.6 mg/mL, 0.7 mg/mL, 0.8 mg/mL, 0.9 mg/mL, 1.0 mg/mL, 1.1 mg/mL, 1.2 mg/mL, 1.3 mg/mL, 1.4 mg/mL, 1.5 mg/mL, 1.6 mg/mL, 1.7 mg/mL, 1.8 mg/mL, 1.9 mg/mL, 2.0 mg/mL, 2.1 mg/mL, 2.2 mg/mL, 2.3 mg/mL, 2.4 mg/mL, 2.5 mg/mL, 2.6 mg/mL, 2.7 mg/mL, 2.8 mg/mL, 2.9 mg/mL, 3.0 mg/mL, 3.1 mg/mL, 3.2 mg/mL, 3.3 mg/mL, 3.4 mg/mL, 3.5 mg/mL, 3.6
  • a clinical sample container comprises 0.01% - 1.00% concentration of a first PP after a clinical sample (e.g., whole blood) is added.
  • a clinical sample container comprises 0.05% - 0.95%, 0.10% - 0.90%, 0.15% - 0.85%, 0.20% - 0.80%, 0.25% - 0.75%, 0.30% - 0.70%, 0.35% - 0.65%, 0.40% - 0.60%, 0.45% - 0.55% of a first PP after a clinical sample is added.
  • a clinical sample container comprises 0.01%, 0.03%, 0.05%, 0.07%, 0.09%, 0.11%, 0.13%, 0.15%, 0.17%, 0.19%, 0.21%, 0.23%, 0.25%, 0.27%, 0.29%, 0.31%, 0.33%, 0.35%, 0.37%, 0.39%,
  • PPs may be added to a clinical sample already containing one or more PPs in a single addition or in multiple (e.g., 2 or more) additions. These multiple PPs additions may be simultaneous or non-simultaneous. Simultaneous means that multiple PP additions occur at exactly the same time. Non-simultaneous means that multiple PP additions occur at different times that are separated by e.g., seconds, minutes, hours, or more. Multiple additions that are simultaneously added may mean that one or more PPs are encapsulated in separate devices (e.g., tube, pipette tip, etc.), and their addition occurs at the same time. Multiple additions that are non-simultaneous may be that one or more PPs are encapsulated in separate devices and their addition does not occur at the same time.
  • simultaneous additions that are simultaneously added may mean that one or more PPs are encapsulated in separate devices (e.g., tube, pipette tip, etc
  • PPs added to a clinical sample may be the same PP as is already in the clinical sample or a different PP that is already in the clinical sample. In some embodiments, the same PP as is already in a clinical sample is added to a clinical sample. In some embodiments, a different PP is added to a clinical sample compared to the PP already in the clinical sample.
  • a clinical sample container comprises a first PP and a second PP is added to the clinical sample. The first PP and the second PP may be the same PP or different PPs. In some embodiments, the first PP and the second PP are the same. In some embodiments, the first PP and the second PP are different.
  • To a clinical sample comprising the first PP may be added up 1-10 different PPs.
  • 1-10 different PPs, 2-9 different PPs, 3-8 different PPs, 4-7 different PPs, or 5-6 different PPs may be added to a clinical sample comprising the first PP.
  • 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 or more different PPs are added to a clinical sample comprising a first PP.
  • 1-10 different PPs are added to a clinical sample at an aggregate concentration of 0.05 mg/mL - 5.0 mg/mL of 1-10 different PPs. In some embodiments, 1-10 different PPs are added to a clinical sample at an aggregate concentration of 0.10 mg/mL - 4.9 mg/mL, 0.20 mg/mL - 4.8 mg/mL, 0.30 mg/mL - 4.7 mg/mL, 0.40 mg/mL - 4.6 mg/mL, 0.50 mg/mL - 4.5 mg/mL, 0.6 mg/mL - 4.4 mg/mL, 0.7 mg/mL - 4.3 mg/mL, 0.8 mg/mL - 4.2 mg/mL, 0.9 mg/mL - 4.1 mg/mL, 1.0 mg/mL, 4.0 mg/mL, 1.1 mg/mL - 3.9 mg/mL, 1.2 mg/mL - 3.8 mg/mL, 1.3 mg/
  • a clinical sample container comprises 0.1 mg/mL, 0.2 mg/mL, 0.3 mg/mL, 0.4 mg/mL, 0.5 mg/mL, 0.6 mg/mL, 0.7 mg/mL, 0.8 mg/mL, 0.9 mg/mL, 1.0 mg/mL, 1.1 mg/mL, 1.2 mg/mL, 1.3 mg/mL, 1.4 mg/mL, 1.5 mg/mL, 1.6 mg/mL, 1.7 mg/mL, 1.8 mg/mL, 1.9 mg/mL, 2.0 mg/mL, 2.1 mg/mL, 2.2 mg/mL, 2.3 mg/mL, 2.4 mg/mL, 2.5 mg/mL, 2.6 mg/mL, 2.7 mg/mL, 2.8 mg/mL, 2.9 mg/mL, 3.0 mg/mL, 3.1 mg/mL, 3.2 mg/mL, 3.3 mg/mL, 3.4 mg/mL, 3.5 mg/mL, 3.6
  • 1-10 different PPs are added to a clinical sample in 0.1% - 50% of the total concentration of the first PP. In some embodiments, 1-10 different PPs are added to a clinical sample in 0.1% - 49%, 0.5% - 48%, 1% - 47%, 2% - 46%, 3% - 45%, 4% - 44%, 5% - 43%, 6% - 42%, 7% - 41%, 8% - 40%, 9% - 39%, 10% - 38%, 11% - 37%, 12% - 36%, 13% - 35%, 14% - 34%, 15% - 33%, 16% - 32%, 17% - 31%, 18% - 30%, 19% - 29%, 20% - 28%, 21% - 27%, 22% - 26%, 23% - 25% of the total concentration of the first PP.
  • 1-10 different PPs are added to a clinical sample in 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, or 50% or more of the total concentration.
  • 1-10 different PPs are added to a clinical sample in 1% - 500% of the total volume of the first PP. In some embodiments, 1-10 different PPs are added to a clinical sample in 5% - 495%, 10% - 490%, 20% - 480%, 30% - 470%, 40% - 460%, 50% - 450%, 60% - 440%, 70% - 430%, 80% - 420%, 90% - 410%, 100% - 400%, 110% - 390%, 120% - 380%, 130% - 370%, 140% - 360%, 150% - 350%, 160% - 340%, 170% - 330%, 180% - 320%, 190% - 310%, 200% - 300%, 210% - 290%, 220% - 280%, 230% - 270%, 240% - 260% of the total volume of the first PP.
  • 1-10 different PPs are added to a clinical sample in 1%, 5,%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 110%, 120%, 130%, 140%, 150%, 160%, 170%, 180%, 190%, 200%, 210%, 220%, 230%, 240%, 250%, 260%, 270%, 280%, 290%, 300%, 310%, 320%, 330%, 340%, 350%, 360%, 370%, 380%, 390%, 400%, 410%, 420%, 430%, 440%, 450%, 460%, 470%, 480%, 490%, 500% or more of the total volume of the first PP.
  • 1-10 different PPs are added to a clinical sample in 1%
  • 1-10 different PPs are added to a clinical sample in 5% - 495%, 10% - 490%, 20% - 480%, 30% - 470%, 40% - 460%, 50% - 450%, 60% - 440%, 70% - 430%, 80% - 420%, 90% - 410%, 100% - 400%, 110% - 390%, 120% - 380%, 130% - 370%, 140% - 360%, 150% - 350%, 160% - 340%, 170% - 330%, 180% - 320%, 190% - 310%, 200% - 300%, 210% - 290%, 220% - 280%, 230% - 270%, 240% - 260% of the total concentration of the first PP.
  • 1-10 different PPs are added to a clinical sample in 1%, 5,%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 110%, 120%, 130%, 140%, 150%, 160%, 170%, 180%, 190%, 200%, 210%, 220%, 230%, 240%, 250%, 260%, 270%, 280%, 290%, 300%, 310%, 320%, 330%, 340%, 350%, 360%, 370%, 380%, 390%, 400%, 410%, 420%, 430%, 440%, 450%, 460%, 470%, 480%, 490%, 500% or more of the total concentration of the first PP.
  • 1-10 different PPs are added to a clinical sample in 1%
  • - 500% of the total volume of a clinical sample comprising a first PP 1-10 different PPs are added to a clinical sample in 5% - 495%, 10% - 490%, 20% - 480%, 30% - 470%, 40% - 460%, 50% - 450%, 60% - 440%, 70% - 430%, 80% - 420%, 90% - 410%, 100% - 400%, 110% - 390%, 120% - 380%, 130% - 370%, 140% - 360%, 150% - 350%, 160% - 340%, 170% - 330%, 180% - 320%, 190% - 310%, 200% - 300%, 210% - 290%, 220% - 280%, 230% - 270%, 240% - 260% of the total volume of a clinical sample comprising a first PP.
  • 1-10 different PPs are added to a clinical sample in 1%, 5,%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 110%, 120%, 130%, 140%, 150%, 160%, 170%, 180%, 190%, 200%, 210%, 220%, 230%, 240%, 250%, 260%, 270%, 280%, 290%, 300%, 310%, 320%, 330%, 340%, 350%, 360%, 370%, 380%, 390%, 400%, 410%, 420%, 430%, 440%, 450%, 460%, 470%, 480%, 490%, 500% or more of the total volume of a clinical sample comprising a first PP.
  • Adding 1-10 different PPs to a clinical sample comprising a first PP inhibits or prevents the formation of macromolecular aggregates comprising the first PP ( Figures 1A, IB).
  • the PPs can be removed from the clinical sample because the PPs are inhibited or prevented from forming macromolecular aggregates. This removal may be by any method known in the art.
  • Non-limiting methods of removing PPs from a clinical sample include: splitting a clinical sample into multiple fractions, binding of the PPs with a protein (e.g., bovine serum albumin, human serum albumin, etc.), and affinity-based separation (e.g., antibody-based binding, magnetic bead binding).
  • a protein e.g., bovine serum albumin, human serum albumin, etc.
  • affinity-based separation e.g., antibody-based binding, magnetic bead binding.
  • removal of a PP from a clinical sample comprises removing a fraction comprising a first PP and a second PP from a clinical sample.
  • the clinical sample may comprise one or more microbial species.
  • a clinical sample comprising a first PP and 1-10 different PPs is separated into multiple fractions. This separation may be by any method known in the art including, but not limited to: velocity sedimentation and size exclusion chromatography.
  • a clinical sample comprising a first PP and 1-10 different PPs is separated into multiple fractions by velocity sedimentation.
  • a clinical sample is separated into a first fraction comprising one or more microbial species and cells from a subject and a 2-10 additional fractions comprising the 1-10 different PPs.
  • a clinical sample is split into at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, or more fractions. In some embodiments, a clinical sample is split into 2-3, 2-4, 2-5, 2-6, 2-7, 2-8, 2-9, 2-10, 3-4,
  • a clinical sample is split into at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, or more fractions that are equal in weight and/or volume. In some embodiments, a clinical sample is split into at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, or more fractions.
  • a clinical sample is split into 2-3, 2-4, 2-5, 2-6, 2-7, 2- 8, 2-9, 2-10, 3-4, 3-5, 3-6, 3-7, 3-8, 3-9, 3-10, 4-5, 4-6, 4-7, 4-8, 4-9, 4-10, 5-6, 5-7, 5-8, 5-9, 5-10, 6-7, 6-8, 6-9, 6-10, 7-8, 7-9, 7-10, 8-9, 8-10, or 9-10 fractions that are equal in weight and/or volume.
  • a clinical sample is split into at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, or more fractions that are unequal in weight and/or volume. In some embodiments, a clinical sample is split into 2, 3, 4, 5, 6, 7, 8, 9, 10, or more fractions. In some embodiments, a clinical sample is split into 2-3, 2-4, 2-5, 2-6, 2-7, 2-8, 2-9, 2-10, 3-4, 3-5, 3-6, 3-7, 3-8, 3-9, 3-10, 4-5, 4-6, 4-7, 4-8, 4-9,
  • a clinical sample is split into at least a first fraction (e.g., fraction 1) comprising one or more microbial species and cells from the subject and a second fraction (e.g., fraction 2) comprising 1-10 PPs.
  • the present disclosure provides a method for removing a polyanionic polymer from a clinical sample, the method comprising: (i) obtaining a clinical sample from a subject comprising one or more microbial species in a container comprising 0.01% - 1.00% of a first polyanionic polymer; (ii) adding between 0.1% - 10% of a second polyanionic polymer to the clinical sample; (iii) removing from the clinical sample from step (ii) a first fraction comprising the first polyanionic polymer and the second polyanionic polymer.
  • the present disclosure provides a method for removing a polyanionic polymer from a clinical sample, the method comprising: (i) obtaining a clinical sample from a subject comprising one or more microbial species in a container comprising 0.01% - 1.00% of a first polyanionic polymer nucleic acid amplification inhibitor; (ii) adding between 0.1% - 10% of a second polyanionic polymer nucleic acid amplification inhibitor to the clinical sample; (iii) separating the clinical sample from step (ii) into a first fraction comprising the one or more microbial species and cells from the subject and a second fraction comprising the first polyanionic polymer nucleic acid amplification inhibitor and the second polyanionic polymer nucleic acid inhibitor; and (iv) removing the second fraction from the clinical sample in step (iii).
  • polycationic and/or zwitterionic polymers may also be removed from a clinical sample according to any method provided herein.
  • Polycationic polymers are compounds composed of monomers comprising one or more positive charges.
  • a poly cationic polymer may be any polycationic polymer known in the art in clinical sample processing.
  • Non-limiting examples of polycationic polymers include: polyamidoamine, polyethylenimine (PEI), mannosylated PEI, poly(L- lysine), and poly(P-amino ester).
  • Zwitterionic polymers are compounds composed of monomers comprising one or more positive charges and one or more negative charges, wherein the polymer has an overall net neutral charge.
  • methods provided herein include separating a clinical sample comprising 1-10 PPs to remove the 1-10 PPs from microbial cells and human cells into a fraction(s) comprising one or more microbial cells and subject cells and a fraction(s) comprising the 1-10 PPs.
  • the fraction(s) comprising microbial cells and subject cells is removed from a fraction comprising the 1-10 PPs, or a fraction(s) comprising the 1-10 PPs is removed from a fraction(s) comprising microbial cells and subject cells.
  • the term “separating”, as used herein, refers to the process of physically separating two or more substances (e.g., microbial cells and subject cells, 1-10 PPs).
  • separating may include centrifugation (e.g., velocity sedimentation), separating supernatant (e.g., from a pellet), and moving the supernatant to a separate tube (e.g., from the pellet), filtration, nucleic acid (e.g., DNA or RNA) isolation, or any combination thereof.
  • centrifugation e.g., velocity sedimentation
  • separating supernatant e.g., from a pellet
  • a separate tube e.g., from the pellet
  • nucleic acid e.g., DNA or RNA
  • separating may include one or more centrifugation steps, such as velocity sedimentation.
  • Velocity sedimentation also known as rate-zonal centrifugation, is a technique used to separate particles in a solution based on their size and shape, where larger molecules accumulate in a pellet at the bottom of the container (e.g., tube) being centrifuged and smaller molecules accumulate in the supernatant above the pellet.
  • This method can be employed to fractionate macromolecules (e.g., proteins, nucleic acids, or subcellular organelles) according to their sedimentation rates in a centrifugal field.
  • centrifugation may be used to compact human cells and microbial cells in the bottom of a container (e.g., tube).
  • a method of the present disclosure may further comprise removing supernatant from above the compacted human cells (e.g., comprising 1-10 PPs and placing it into a separate tube.
  • methods provided herein include removing a fraction from a clinical sample.
  • removing or “remove” means that separating a clinical sample (e.g., into fractions) and reducing or eliminating one or more PPs. Removing need not mean 100% separation and reduction of one or more PPs.
  • removing is 99%, 98%, 97%, 96%, 95%, 94%, 93%, 92%, 91%, 90%, 89%, 88%, 87%, 86%, 85%, 84%, 83%, 82%, 81%, 80%, 79%, 78%, 77%, 76%, 75%, 74%, 73%, 72%, 71%, 70%, 69%, 68%, 67%, 66%, 65%, 64%, 63%, 62%, 61%, 60%, 59%, 58%, 57%, 56%, 55%, 54%, 53%, 52%, 51%, 50%, 49%, 48%, 47%, 46%, 45%, 44%, 43%, 42%, 41%, or 40% separation and reduction of one or more PPs.
  • Removing may include separating a supernatant (e.g., from a pellet). Separating a supernatant typically involves the separation of a liquid (e.g., comprising 1-10 PPs) from solid particles (e.g., the pellet containing human cells and microbial cells) that have settled at the bottom of a container. The supernatant can be separated by decanting the supernatant into a new container or by pipetting (e.g., using a Pasteur pipette or a micropipette).
  • a supernatant typically involves the separation of a liquid (e.g., comprising 1-10 PPs) from solid particles (e.g., the pellet containing human cells and microbial cells) that have settled at the bottom of a container.
  • the supernatant can be separated by decanting the supernatant into a new container or by pipetting (e.g., using a Pasteur pipette or a micropipette).
  • removing may include filtration, whereby a sample is passed through a filter with a specific pore size that retains one or more microbial species (e.g., bacteria, virus, fungus, or parasite) while allowing other materials to pass through.
  • removing may be performed using a combination of centrifugation, filtration, and/or separating a supernatant.
  • removing may include nucleic acid (e.g., DNA or RNA) isolation.
  • Nucleic acid isolation (also known as nucleic acid extraction), is a technique used to obtain DNA or RNA from a biological sample.
  • the DNA or RNA that is isolated can be derived from the subject (e.g., a human subject) or from microbial species (e.g., bacteria, viruses, fungi, or parasites).
  • Methods of performing nucleic acid isolation are known to those of skill in the art and can include, but are not limited to, phenol-chloroform extraction, silica- based spin columns, magnetic bead-based purification, organic solvent precipitation, solidphase extraction, and ultracentrifugation.
  • Methods provided herein include lysing cells (e.g., human cells, microbial cells) in a clinical sample (e.g., blood or urine).
  • lysing refers to the breaking down or rupturing of a cell’s membranes to release its contents (e.g., DNA, RNA, proteins).
  • the subject (e.g., human) and microbial (e.g., bacteria, virus, or fungus) cells can be differentially lysed and fractioned based on their specific properties, such as size, density, or other chemical properties, including cell membrane or cell wall composition.
  • cell lysis e.g., homogenization
  • chemical cell lysis e.g., detergent lysis, such as with Triton X-100 or sodium dodecyl sulfate (SDS)
  • enzymatic cell lysis e.g., using lysozyme
  • freeze-thaw lysis ultrasonication, high-pressure homogenization, osmotic shock, or electroporation.
  • methods provided herein include lysing cells (e.g., human cells, microbial cells). In some embodiments, methods provided herein include lysing cells (e.g., human cells, microbial cells) in a fraction (e.g., a first fraction) in the presence of a first detergent.
  • Detergents are chemical compounds containing amphiphilic molecules that enable the disruption of cell membranes due to their ability to interact with and solubilize molecules or structures that are not water soluble.
  • the detergent is a nonionic detergent.
  • a nonionic detergent is a detergent that does not carry a net electrical charge and is typically milder than ionic detergents.
  • nonionic detergent is not as strong and will not disrupt cell membranes to the same degree as an ionic detergent.
  • Non-limiting examples of nonionic detergents include Triton X-100 and NP-40.
  • the detergent is an ionic detergent. Ionic detergents are generally harsher than nonionic detergents.
  • This class of detergents can be further subdivided into anionic detergents (e.g., sodium dodecyl sulfate (SDS), ammonium dodecyl sulfate (ADS), sodium lauryl sulfate (SLS), cetylpyridinium chloride), cationic detergents (e.g., cetyltrimethylammonium bromide (CTAB), benzyldimethyloctylammonium chloride), and zwitterionic detergents (e.g., CHAPS, pentaerythrityl palmitate).
  • anionic detergents e.g., sodium dodecyl sulfate (SDS), ammonium dodecyl sulfate (ADS), sodium lauryl sulfate (SLS), cetylpyridinium chloride
  • cationic detergents e.g., cetyltrimethylammonium bromide (CTAB), benzyldimethyloct
  • methods provided herein include lysing cells (e.g., human cells, microbial cells) in a fraction (e.g., a first fraction or a second fraction) in the presence of a second detergent and a surfactant.
  • a surfactant is a compound used to alter the surface properties of liquids and can facilitate the disruption of cell membranes due to their ability to solubilize lipids and prevent the clumping and/or aggregation of cellular material.
  • the presence of a surfactant protects non-human cells (e.g., cells of one or more microbial species) from lysis.
  • the presence of a surfactant does not protect non-human cells (e.g., cells of one or more microbial species) from lysis.
  • non-human cells e.g., cells of one or more microbial species
  • surfactants include Tween-20 (polysorbate-20), Tween-80 (polysorbate-80), NP-40, and Triton X-100.
  • Other surfactants known in the art are contemplated.
  • methods of the present disclosure include amplifying microbial DNA from lysed microbial species.
  • Amplifying DNA means that the amount of DNA (e.g., in a fraction) is increased by an enzymatic reaction.
  • methods for amplifying microbial DNA include polymerase chain reaction (PCR), quantitative PCR (qPCR), reverse-transcriptase PCR (RT-PCR), degenerate oligonucleotide PCR, primer extension pre-amplification, strand displacement amplification (SDA), helicase dependent amplification (HAD), transcription mediated amplification (TMA), recombinase polymerase amplification (RPA), loop-mediated isothermal amplification (LAMP), whole genome amplification (WGA), multiple displacement amplification (MDA), random amplification of polymorphic DNA (RAPD), restriction fragment length polymorphism (RFLP), and rolling circle amplification (RCA).
  • PCR polymerase chain reaction
  • qPCR quantitative PCR
  • RT-PCR
  • the amount of amplified microbial DNA is increased 2-fold - 200-fold compared to control (e.g., as a result of adding a polyanionic polymer to a clinical sample).
  • the amount of amplified microbial DNA is increased 5-fold - 190-fold, 10-fold - 180-fold, 20-fold - 170-fold, 30-fold - 160- fold, 40-fold - 150-fold, 50-fold - 140-fold, 60-fold - 130-fold, 70-fold - 120-fold, 80-fold - 110-fold, or 90-fold - 100-fold compared to control.
  • the amount of amplified microbial DNA is increased 2-fold, 5-fold, 10-fold, 15-fold, 20-fold, 25-fold, 30- fold, 35-fold, 40-fold, 45-fold, 50-fold, 55-fold, 60-fold, 65-fold, 70-fold, 75-fold, 80-fold, 85-fold, 90-fold, 95-fold, 100-fold, 105-fold, 110-fold, 115-fold, 120-fold, 125-fold, 130- fold, 135-fold, 140-fold, 145-fold, 150-fold, 155-fold, 160-fold, 165-fold, 170-fold, 175-fold, 180-fold, 185-fold, 190-fold, 195-fold, or 200-fold compared to control.
  • the amount of amplified microbial DNA is increased 25% - 1000% compared to control (e.g., as a result of adding a polyanionic polymer to a clinical sample). In some embodiments, the amount of amplified microbial DNA is increased 50% - 950%, 100% - 900%, 150% - 850%, 200% - 800%, 250% - 750%, 300% - 700%, 350% - 650%, 400% - 600%, or 450% - 550% compared to control.
  • the amount of amplified microbial DNA is increased 25%, 50%, 75%, 100%, 125%, 150%, 175%, 200%, 225%, 250%, 275%, 300%, 325%, 350%, 375%, 400%, 425%, 450%, 475%, 500%, 525%, 550%, 575%, 600%, 625%, 650%, 675%, 700%, 725%, 750%, 775%, 800%, 825%, 850%, 875%, 900%, 925%, 950%, 975%, or 1000% or more compared to control.
  • a control may be a clinical sample that has one or more PPs at a lower concentration than a clinical sample provided herein.
  • a control may have 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%,
  • Methods provided herein include identifying one or more microbial species.
  • identifying refers to confirming the presence of one or more microbial species (e.g., bacteria, virus, fungus, or parasite) in a sample (e.g., clinical sample).
  • amplified DNA e.g., microbial DNA
  • identification of amplified DNA refers to confirmation of the presence of specific DNA sequences (occurring in a specific microbe) in a sample following DNA amplification. The identification can be qualitative, to confirm the presence or absence of the target DNA sequence, or quantitative, to provide information about the amount or concentration of the amplified DNA.
  • Methods of detecting amplified DNA include, but are not limited to, agarose gel electrophoresis, polyacrylamide gel electrophoresis, ethidium bromide staining, SYBR green staining, fluorescent probes (e.g., TaqMan probes, molecular beacons, dual-labeled probes), DNA intercalating dyes (e.g., EvaGreen or SYBR Safe), DNA fragment analysis (e.g., capillary electrophoresis), real-time PCR (qPCR), digital PCR, nucleic acid hybridization (e.g., microarrays), enzyme-linked immunosorbent assays (ELISA), microscopy, or next-generation sequencing (e.g., Illumina sequencing or Nanopore sequencing).
  • agarose gel electrophoresis e.g., polyacrylamide gel electrophoresis, ethidium bromide staining, SYBR green staining, fluorescent probes (e.g., TaqMan probes, molecular beacon
  • one or more microbial species are detected using sequencing (e.g., next-generation sequencing (NGS)). Sequencing data from clinical samples is analyzed to measure the breadth of coverage of a microbial species genome in the sequencing data.
  • NGS next-generation sequencing
  • This approach is particularly advantageous in sequencing data obtained from clinical samples, which may include human DNA and other confounding DNA sources in addition to DNA from one or more microbial species.
  • contaminating DNA e.g., human DNA, confounding DNA
  • only microbial species with a 0.5x - lOx microbial genome coverage are identified in the present disclosure.
  • Ox or more microbial genome coverage are identified in the present disclosure.
  • Sequencing reads following processing of a clinical sample are aligned to reference genomes from one or more microbial species. This alignment may be performed manually or by using an open-source software tool (e.g., Microbe-ID, DAMIAN, MIST, IDseq, mothur).
  • the breadth of coverage of a microbial species may be calculated by simply counting sequencing reads for each microbial species or by reconstructing the whole genome of the one or more microbial species from sequencing reads in the clinical sample.
  • Reconstructing the whole genome of one or more microbial species may be performed using an open-source software tool (e.g., flye, Canu, Raven, Shasta, Miniasm) or manually. Once a whole genome of one or more microbial species is reconstructed, the one or more microbial species may be identified using an open-source software tool (e.g., Kraken) or manually.
  • an open-source software tool e.g., Kraken
  • the genome coverage of the amplified microbial DNA is at least 0.8x, at least 0.9x, at least l.Ox, at least 1.5x, at least 2. Ox, at least 2.5x, at least 3.
  • the genome coverage of the amplified microbial DNA is 0.8x - 0.9x, 0.8x - l.Ox, 0.8x -1.5x, 0.8x - 2.
  • Methods provided herein include enriching, identifying and/or quantifying one or more microbial species in a clinical sample.
  • microbial species is any microorganism that is present in a sample (e.g., a clinical sample).
  • the microbial species is a bacteria, a virus, a fungus, a parasite, or any combination thereof.
  • the microbial species present in a sample may be a commensal organism, which is a microorganism (e.g., bacteria, virus, fungus, or parasite) that lives in or on a subject without causing harm to the host or providing any significant benefits, or may be a pathogenic organism, which is a microorganism (e.g., bacteria, virus, fungus, mold, or parasite) that has disease-causing potential.
  • a microorganism e.g., bacteria, virus, fungus, or parasite
  • pathogenic organism which is a microorganism (e.g., bacteria, virus, fungus, mold, or parasite) that has disease-causing potential.
  • pathogenic organism or “pathogenic microbial species”, are used interchangeably herein and refer to a microorganism (e.g., bacteria, virus, fungus, or parasite), that has the ability to cause disease in a subject by invading, colonizing, and/or multiplying within the subject, leading to various illnesses or infections.
  • a commensal organism can turn into a pathogenic organism in a process referred to as “commensal -to-pathogen transition”.
  • Non-limiting factors contributing to this shift include: i) genetic mutations that may result in the acquisition of new genes or the loss of genes that regulate virulence, increasing the organism’s pathogenic potential; ii) horizontal gene transfer, in which a commensal organism acquires virulence factors or antibiotic resistance genes from another microorganism; iii) changes in environmental conditions, such as antibiotic use or immune system suppression; and, iv) microbiota dysbiosis, in which alterations in a host’s microbiome composition and diversity creates opportunities for commensal organisms to complete with or displace other microorganisms.
  • one or more microbial species in a clinical sample provided herein is a pathogenic microbial species.
  • One microbial species or multiple microbial species in a clinical sample may be pathogenic.
  • 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 or more microbial species are pathogenic microbial species.
  • a pathogenic microbial species is a virus. In some embodiments, a pathogenic microbial species is a fungus. In some embodiments, a pathogenic microbial species is a parasite.
  • a method for removing a PP form a clinical sample comprises obtaining a clinical sample comprising one or more microbial species from a subject.
  • obtaining refers to collecting a clinical sample (e.g., blood or urine) from a subject at a designated time.
  • a clinical sample is a biological sample obtained from a subject.
  • Non-limiting examples of clinical samples include a blood sample (e.g., whole blood, plasma, or serum), a urine sample, a saliva sample, a stool sample, a cerebrospinal fluid sample, a throat swab sample, an oral swab sample, a bronchial lavage sample.
  • a clinical sample is a blood sample, wherein the blood sample is a whole blood sample, a plasma sample, or a serum sample.
  • the blood sample is obtained from a subject by venipuncture or finger prick.
  • a clinical sample is a urine sample, wherein the urine sample is obtained by midstream urine collection, catheterization (e.g., using a Foley catheter), or bladder puncture.
  • a clinical sample may, in some embodiments, contain low levels of commensal bacteria from the skin and/or urinary tract microbiome.
  • Methods provided herein include obtaining a clinical sample from a subject.
  • a subject may be any organism that can be infected by a microbial species.
  • the subject is a mammal.
  • the subject is a non-human primate (e.g., a laboratory animal such as a rhesus monkey).
  • the subject is a rodent, such as a rat or mouse.
  • the subject is a goat, rabbit, sheep, or pig.
  • the subject is a human.
  • SPS Sodium polyanethol sulfonate
  • SPS is a polyanionic polymer widely used as an anticoagulant in blood collection containers.
  • solids e.g., red blood cells and white blood cells, etc.
  • liquids e.g., plasma, small molecular weight nucleic acid amplification inhibitors, etc.
  • persistence of SPS in the liquid phase can block downstream processes such as nucleic acid amplification.
  • SPS is soluble in water, but not in alcohol, thus it tends to copurify with DNA during whole genome amplification processes.
  • removal of SPS from the molecular reactions during the genome amplification, or mitigation of its presence during sample processing is imperative.
  • Each sample was treated with 0%, 0.5%, 1%, or 5% SPS.
  • Clinical sample processing was performed to remove human cells and concentrate the remaining bacterial cells. These bacterial cells were lysed at 37°C.
  • Bacterial DNA from lysed bacterial cells was concentrated and subjected to REPLI-g Single Cell MDA. Total amplified DNA was quantified using the Qubit dsDNAHS Assay kit (ThermoFisher, Waltham, MA).
  • dsDNA double-stranded DNA
  • MB total megabase
  • dsDNA concentration in the blood samples treated with 0.5%, 1% or 5% SPS was increased by at least 100-fold compared to a 0% SPS control sample (Figs. 2A and 2B).
  • Bacterial whole genome coverage values in blood samples treated with 0.5%, 1% and 5% SPS are significantly high as compared to 0% SPS control (Fig. 2C).
  • Ethylenediaminetetraacetic acid (EDTA), heparin, and anticoagulant citrate dextrose solution (ACD-A) are other commonly-used anticoagulants.
  • Clinical blood sample collection tubes containing EDTA, heparin, and ACD-A were tested for efficacy in preservation of intact microbial cells and extraction of DNA for amplification.
  • Whole blood samples from a healthy donor were collected in vacuum liquid containers containing SPS, ACD-A, EDTA, or heparin.
  • the experimental samples were processed as described above.
  • Fig. 3 shows that high concentration SPS produces significantly increased microbial DNA identification using SPS containing vacutainers as compared to ACD-A, EDTA or heparin containing vacutainers.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Plant Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente divulgation concerne l'élimination d'un premier polymère polyanionique d'un échantillon clinique par ajout d'un second polymère polyanionique à l'échantillon clinique, ledit second polymère polyanionique pouvant être identique ou différent du premier polymère polyanionique.
PCT/US2024/056879 2023-11-22 2024-11-21 Atténuation de sps Pending WO2025111453A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363601959P 2023-11-22 2023-11-22
US63/601,959 2023-11-22

Publications (1)

Publication Number Publication Date
WO2025111453A1 true WO2025111453A1 (fr) 2025-05-30

Family

ID=95827168

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2024/056879 Pending WO2025111453A1 (fr) 2023-11-22 2024-11-21 Atténuation de sps

Country Status (1)

Country Link
WO (1) WO2025111453A1 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020176822A1 (fr) * 2019-02-28 2020-09-03 Day Zero Diagnostics, Inc. Procédé amélioré de préparation d'échantillons cliniques pour amplification d'acide nucléique
US20210208128A1 (en) * 2018-05-25 2021-07-08 Qvella Corporation Methods and compositions for the selective lysis of blood cells and separation of microbial cells

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210208128A1 (en) * 2018-05-25 2021-07-08 Qvella Corporation Methods and compositions for the selective lysis of blood cells and separation of microbial cells
WO2020176822A1 (fr) * 2019-02-28 2020-09-03 Day Zero Diagnostics, Inc. Procédé amélioré de préparation d'échantillons cliniques pour amplification d'acide nucléique

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ANNA K. BOARDMAN, JENNIFER CAMPBELL, HOLGER WIRZ, ANDRE SHARON, ALEXIS F. SAUER-BUDGE: "Rapid Microbial Sample Preparation from Blood Using a Novel Concentration Device", PLOS ONE, vol. 10, no. 2, pages e0116837, XP055428858, DOI: 10.1371/journal.pone.0116837 *

Similar Documents

Publication Publication Date Title
JP6670765B2 (ja) 生物試料中の核酸を安定化する組成物および方法
JP6153516B2 (ja) イオン性界面活性剤による細胞の選択的溶解
US10308976B2 (en) Selective lysis of cells
CA2892813C (fr) Appareil et procede de pretraitement d'echantillons microbiens
CN102888394B (zh) 核酸提取方法和核酸提取筒
CN113073096A (zh) 一种血液中病原微生物分离、富集和核酸提取方法及试剂
EP2245157A1 (fr) Procédé pour l'extraction et la purification d'acides nucléiques sur une membrane
US20230416722A1 (en) Apparatus and method for pretreatment of microbial samples
Sun et al. Efficient purification and concentration of viruses from a large body of high turbidity seawater
US20240068050A1 (en) Methods and devices for identifying microbial infections
WO2013177277A1 (fr) Concentration microbienne utilisant de l'acide poly-l-glutamique (pga) pour éviter la centrifugation
EP2547767A2 (fr) Utilisation d'une achromopeptidase pour une lyse à température ambiante
US9707555B2 (en) Method for pretreatment of microbial samples
Sharma et al. Evaluation of polymerase chain reaction using protein b primers for rapid diagnosis of tuberculous meningitis
WO2025111453A1 (fr) Atténuation de sps
US12344834B2 (en) Phylogenetic-based differential cell separation and DNA extraction
CN110819625A (zh) 一种适用于细菌和/或真菌的基因组dna提取方法
US20240025929A1 (en) Methods and devices for ultrasensitive direct detection of microorganisms
WO2016148089A1 (fr) Procédé de détection d'une cible de détection à l'aide de nanoparticules magnétiques sensibles à une stimulation
WO2021087174A1 (fr) Procédé et kit pour la détection directe de maladies d'origine bactérienne du sang
Kapustin et al. High-throughput method of one-step DNA isolation for PCR diagnostics of Mycobacterium tuberculosis
CN118995383B (zh) 一种磁珠法微生物基因组提取试剂盒及微生物基因组提取方法
WO2014018435A1 (fr) Isolation et récupération de micro-organisme au moyen de particules sorbantes

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24895051

Country of ref document: EP

Kind code of ref document: A1